论文部分内容阅读
目的探讨人表皮生长因子受体3(HER3)在人表皮生长因子受体2(HER2)阳性乳腺癌组织中的表达变化及意义。方法回顾性分析2007年2月—2011年10月南阳市第一人民医院206例HER2阳性乳腺癌患者手术组织标本,采用免疫组化染色检测HER3表达,分析Luminal B型(HER2+,n=118)及HER2过表达型(n=88)乳腺癌中HER3表达与临床病理特征关系。结果 Luminal B型(HER2+)型乳腺癌患者HER3阳性表达率为73.73%(87/118),明显低于HER2过表达型85.23%(75/88),差异有统计学意义(P<0.05);Luminal B型(HER2+)组中HER3(-)与HER3(+)型乳腺癌患者在淋巴结转移及组织学分级中表达相比,差异有统计学意义(P<0.05);HER2过表达型组中HER3(-)与HER3(+)型乳腺癌患者在肿块大小、淋巴结转移及组织学分级中表达相比,差异有统计学意义(P<0.05)。结论在HER2阳性乳腺癌中,HER3表达状态可对乳腺癌患者生物学特性进行有效评价。
Objective To investigate the expression and significance of human epidermal growth factor receptor 3 (HER3) in human epidermal growth factor receptor 2 (HER2) positive breast cancer. Methods We retrospectively analyzed 206 cases of HER2-positive breast cancer patients from February 2007 to October 2011 in Nanyang First People’s Hospital. The expression of HER3 in HER2-positive breast cancer patients was detected by immunohistochemistry. Luminal B (HER2 +, n = 118) HER3 expression in HER2 overexpression (n = 88) breast cancer and its clinicopathological characteristics. Results The positive rate of HER3 expression in patients with Luminal type B (HER2 +) breast cancer was 73.73% (87/118), significantly lower than that of HER2 overexpression (85.23%, 75/88). The difference was statistically significant (P <0.05). There were significant differences in the expression of HER3 (-) and HER3 (+) breast cancer in lymph node metastasis and histological grading in the Luminal B type (HER2 +) group (P <0.05); in the HER2 overexpression group The expression of HER3 (-) and HER3 (+) breast cancer in tumor size, lymph node metastasis and histological grade were significantly different (P <0.05). Conclusion In HER2 positive breast cancer, the expression status of HER3 can effectively evaluate the biological characteristics of breast cancer patients.